CYLD: a novel stratification marker for malignant tumors
Author: Shunsuke Miyake, Ayumi Kanemaru, Hideyuki Saito, Hirofumi Jono
Category: Pharmacy
Abstract:
In recent years, many molecular-targeted drugs have been developed, and cancer treatment has advanced enormously. Because intratumoral heterogeneity represents genetic and molecular differences affecting patients’ response to these therapeutic drugs, establishing personalized therapy based on precise molecular pathogenesis is urgently required to maximize the therapeutic effects. Cylindromatosis (CYLD), a tumor suppressor gene, is closely associated with malignant transformation and poor prognosis in various malignant tumors. Increasing clinical evidence suggests that CYLD dysfunction by loss of its expression may play key roles in the molecular pathogenesis of various tumors. Moreover, we recently discovered that loss of CYLD expression not only be involved in malignant transformation, but also serves as a prognostic and predictive biomarker for molecular diagnosis and cancer treatment. In this review, we introduce the clinical significance of CYLD expression in various malignant tumors, and discuss the possibility of personalized therapy focusing on molecular diagnosis using CYLD expression.
